Acumen Pharmaceuticals, Inc. (ABOS) Reports In-Line Q2 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Acumen Pharmaceuticals, Inc. (ABOS) Reports In-Line Q2 EPS

Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2022 and Business Highlights

August 15, 2022 4:05 PM EDT

Topline results expected in the first half of 2023 from INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193 in patients with early Alzheimers disease (AD)
Key methods and assay model developed to potentially standardize the study of soluble amyloid-beta oligomers (AOs) presented in a poster at the recent Alzheimers Association International Conference (AAIC)$209.9 million in cash, cash equivalents and marketable securities as of June 30, 2022, which is expected to provide cash... More